6TH ANNUAL ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE
via Clinical Trials Arena by William Newton. Vosoritide’s uncertain long-term efficacy may limit European coverage of what could be the first drug approved for dwarfism. Need to know Vosoritide is…
Source – Fierce Pharma. While BioMarin bested expectations with its second-quarter performance, the biotech is zeroed in on its two next-gen medicines. And no wonder: Those drugs, Voxogo and Roctavian, could completely…
via Anesthesiology News. Elizabeth A.M. Frost, MD The ninth in a series of capsules of pertinent information and precautions concerning rare disorders for the anesthesiologist. Click here for full article….
If you attended the 2021 Achondroplasia Research Conference, please take a few minutes to complete this survey. By completing this survey, it will help us to know what to bring…
European Commission Decision expected Q3 2021Temporary Authorization for Use (ATU) Granted in France to Allow Access and Reimbursement of Vosoritide to Begin ImmediatelyVosoritide is Potentially the First Medicine to be…
via Johns Hopkins Medicine. In a retrospective study believed to be one of the largest of its kind, researchers say they have successfully charted the health risks, growth patterns, and…